newsfilter
← Latest News
Business Wire·

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

- Topline data from REVEAL anticipated in 2H 2027 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study